Replies to post #201430 on Biotech Values

[DewDiligence]

CHRS—the company who instigated the Humira IPR—is +16%:

http://finance.yahoo.com/news/coherus-biosciences-provides-135-ipr-143152954.html

[DewDiligence]

USPTO rules for ABBV—against CHRS—in Humira IPR re ‘166 patent:

$ABBV --> USPTO denies to institute $CHRS IPR request on Humira '166 patenthttps://t.co/ORelmwF1zO pic.twitter.com/25xNclOlAS

— Andy Biotech (@AndyBiotech) November 7, 2016

This is the opposite result that the USPTO reached on the Humira IPR for the ‘135 patent (#msg-122698047).